At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 469 enrolled
Drug / intervention
GSK A/turkey H5N1 Influenza vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
In Brief
A Phase 2 clinical trial evaluating GSK A/turkey H5N1 Influenza vaccine for Influenza. Completed, enrolled 469 participants across 10 sites in 2 countries.
Detailed Summary
The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartOct 2008
Primary CompletionMay 2009
Study CompletionDec 2009
TodayJul 2026
First PostedOct 13, 2008
Enrollment StartOct 16, 2008
Primary CompletionMay 26, 2009
Study CompletionDec 4, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.7 years ago
Interventions
GSK A/turkey H5N1 Influenza vaccinebiological
One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.